Physician profile
David Brandon Thomas
NPI 1083961601
$657.07
in general payments reported to CMS, 2019-2025
11 companies · $505 in 2025
The $505 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.24 · 2022: $50.79 · 2024: $84.79 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $391 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $391.05 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $229.95 | 2025 | Cresemba |
| Insmed, INC. | $107.29 | 2021-2025 | Arikayce |
| Merck Sharp & Dohme LLC | $55.92 | 2025 | Zerbaxa, Capvaxive, Pifeltro |
| Shionogi INC | $54.36 | 2025 | Fetroja |
| Mindray Ds USA, INC. | $50.79 | 2022 | |
| Gynesonics, INC. | $37.64 | 2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Pfizer INC. | $35.76 | 2025 | |
| Coherus Oncology, INC. | $30.46 | 2025 | Loqtorzi |
| Novavax INC | $23.43 | 2024 | Novavax Covid-19 Vaccine, Adjuvanted |
| Abbvie INC. | $17.17 | 2024 | |
| Legend Biotech USA INC. | $14.30 | 2025 | Carvykti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.